(OCS) Oculis Holding AG Business Model Canvas Research

Oculis Holding AG depends on regulators, ethics committees, and clinical advisers to lock down Phase 3 endpoints, safety rules, and trial design for eye-disease programs. This partnership layer matters most in later-stage filings, where one protocol change can delay a submission by months and raise development risk.

• Align endpoints early
• Clear safety review path
• Support Phase 3 filings

In ophthalmology, tight alignment on visual acuity and retinal safety data helps keep studies decision-ready for regulators.

Oculis Holding AG relies on capital providers and institutional investors to fund R&D because, as a clinical-stage biotech, it has no product sales to finance trials. Public equity support is strategic for pipeline continuity, since drug development can take years before revenue.

• Funds long, pre-revenue R&D
• Supports trial continuity
• Backs equity-based financing

Oculis Holding AG runs multi-site trials, and that means patient recruitment, site monitoring, pharmacovigilance, and database lock must be tight. In 2025, its late-stage work centered on phase 3 programs, so clean data capture is key to keeping regulatory credibility intact.

• Recruit patients across trial sites
• Track safety and adverse events
• Lock databases before filings
• Support phase 3 regulatory proof

Oculis Holding AG must defend formulations, uses, and composition claims around its eye-disease assets, because patent and data protection are central to pricing power and partner interest in ophthalmology. Portfolio discipline matters too: capital should stay focused on the highest-value programs, not spread thin across lower-probability work.

• Protect core formulations and claims
• Use IP to strengthen positioning
• Prioritize the best-value programs

Oculis Holding AG’s intellectual property portfolio is a core asset because patent protection around its formulations and candidate programs helps defend exclusivity, support differentiation, and strengthen future licensing leverage. The portfolio also underpins long-term value assumptions in eye-disease drugs, where patent life and data exclusivity drive peak-sales and royalty economics.

• Protects formulations and candidates
• Supports licensing leverage
• Extends exclusivity assumptions

Oculis Holding AG is headquartered in Zug, Switzerland, giving the Company a stable base for global biotech administration, board oversight, and investor access. The Swiss HQ supports strategic management and corporate governance while keeping leadership close to European capital markets.

• Swiss base for corporate control
• Supports investor relations access
• Anchors global management and governance

Oculis Holding AG’s value proposition is built on topical biologic and neuroprotective innovation, with pipeline assets designed to act through differentiated mechanisms in eye disease. That focus supports a clear positioning around treatments that aim to reach the eye locally and protect vision.

• Topical biologic candidate
• Neuroprotective agent
• Differentiated eye-disease mechanisms
• Innovation-led positioning

Oculis’ value proposition is specialist care for 3 hard-to-treat eye areas: retina, cornea, and optic nerve. Its lead assets target high-unmet-need diseases with few convenient options, so physicians get clearer clinical differentiation.

• 3 specialist disease areas
• High unmet need
• Clear physician differentiation

Oculis Holding AG needs steady regulatory dialogue with the FDA and EMA to keep trial design, endpoints, and safety plans aligned as it advances its eye-disease pipeline. In 2025, that feedback can shift timelines and cost, because even small protocol changes can alter approval paths and the size of later studies.

• Align trials early with regulators
• Reduce rework and delay risk
• Shape approval strategy with feedback

Scientific credibility is a key customer relationship for Oculis Holding AG: in ophthalmology, where WHO estimates 2.2 billion people live with near or distance vision impairment, doctors want strong clinical data before they adopt. Publications and conference talks help validate the assets, and that trust can speed later adoption discussions.

• Clinical evidence drives specialist buy-in.
• Conference visibility builds trust early.
• Credibility can shorten adoption talks.

Oculis Holding AG uses corporate presentations, press releases, and webcast updates to show clinical and cash progress to investors while product sales are still absent. As a pre-commercial biotech, this IR flow helps sustain financing access and market visibility ahead of revenue.

• Pre-sales investor updates build trust.
• Webcasts explain trial and cash milestones.
• Press releases keep market visibility high.

Oculis Holding AG can use partner and licensing outreach to line up future commercialization deals, especially for regional or global rights in ophthalmology, where non-dilutive licensing is common. This channel matters most if Oculis stays non-fully integrated, since a partner can fund sales, market access, and local launch work while Oculis keeps some upside.

• Find regional launch partners
• Outlicense global rights when needed
• Reduce commercial build-out risk
• Keep milestone and royalty upside

Hospitals and academic medical centers are key Oculis Holding AG customers because they handle complex eye-disease cases, run clinical trials, and shape treatment standards. They are especially important in rare and severe diseases, where evidence from specialized sites can speed adoption across care networks and support stronger real-world data.

• Enroll complex, high-need patients
• Support trial recruitment and evidence
• Influence specialty care standards

If approved, Oculis Holding AG would sell to ophthalmologists, retina specialists, hospitals, and buying groups, not to consumers, so adoption depends on prescriber trust and formulary access. Reimbursement also matters: in 2025, about 67 million people were covered by Medicare in the U.S., which makes payer decisions a key gate for eye-care uptake.

• Prescribers drive demand
• Institutions make bulk purchases
• Payers shape access and uptake

Oculis Holding AG’s general and administrative costs cover board oversight, legal, finance, and HR, plus Nasdaq reporting and investor relations. In 2025, these expenses stayed well below R and D but remained material because a Swiss public listing needs ongoing compliance and disclosure work.

• Governance and legal costs are recurring.
• Nasdaq reporting adds fixed overhead.
• Investor relations supports market access.
• G&A stays below R and D.

Regulatory and IP maintenance costs are a steady drag for Oculis Holding AG, but they protect the pipeline and keep each program ready for FDA and EMA review. For a clinical-stage biotech, patent prosecution, legal defense, and regulatory consulting are not optional; they are the spend that shields future revenue and preserves market exclusivity.

• Patent filings and renewals
• IP enforcement and legal defense
• Regulatory strategy and consulting
• Approval-readiness for pipeline assets

Oculis Holding AG’s development and milestone payments come from partner deals that pay when a program hits clinical, regulatory, or commercial steps, so cash is tied to pipeline progress. This can help offset R and D spend, but the stream is uneven and depends on successful trial readouts and approvals.

• Cash arrives at milestone hits.
• Offsets R and D costs.
• Depends on pipeline execution.

If Oculis Holding AG licenses approved assets, royalties can turn into recurring, high-margin income; specialty biotech deals often pay mid-single-digit to low-teens royalties, with the final cash flow tied to market uptake and deal terms. If sales scale, the stream can compound without adding much SG&A.

• Recurring income after approval
• Common biotech monetization model
• Depends on uptake and royalty rate